BiotechTube
Cyclomics

Cyclomics

Utrecht, Netherlands· Est.
cyclomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Cyclomics is a private, early-stage diagnostics company developing innovative liquid biopsy solutions for cancer. Its core technology, CyclomicsSeq, combines molecular barcoding and consensus sequencing on the Nanopore platform to achieve high-accuracy (Q40) detection of rare mutations in blood. The company also offers Epinn, an AI-driven software framework for rapid tumor classification, and provides contract research services. Cyclomics is positioned to address the critical need for more sensitive, accessible, and faster molecular diagnostics in oncology.

Oncology

Technology Platform

Proprietary consensus-sequencing (CyclomicsSeq) and molecular barcoding chemistry optimized for the Oxford Nanopore platform, combined with the Epinn AI-driven software framework for rapid tumor classification and data analysis.

Funding History

1
Total raised:$4.5M
Seed$4.5M

Opportunities

The global liquid biopsy market offers massive growth potential, particularly in early cancer detection and minimal residual disease monitoring where high sensitivity is critical.
Cyclomics's foundation on the portable and cost-effective Nanopore platform also creates an opportunity for decentralized testing and expansion into broader molecular diagnostics applications beyond oncology.

Risk Factors

Key risks include the high technical and clinical validation burden for early detection assays, intense competition from established players using different sequencing technologies, and dependence on the Oxford Nanopore platform's ongoing success and clinical adoption.
As a private startup, securing sufficient funding to reach commercialization milestones is also a persistent risk.

Competitive Landscape

Cyclomics competes in the crowded liquid biopsy space against large, well-capitalized companies like Guardant Health, Freenome, and Exact Sciences, which primarily use Illumina sequencing. Its differentiation lies in its proprietary error-correction on the Nanopore platform, aiming for superior sensitivity at potentially lower cost. It also faces competition from other Nanopore-focused assay developers and bioinformatics firms.

More companies in Diagnostics & Precision Medicine →More companies in Netherlands →